Ocular Therapeutix (OCUL) Receives News Impact Score of 0.19

News articles about Ocular Therapeutix (NASDAQ:OCUL) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ocular Therapeutix earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 16 out of 100, meaning that recent news coverage is very unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern’s analysis:

Shares of Ocular Therapeutix (NASDAQ OCUL) traded down 14.1208% during mid-day trading on Monday, hitting $6.1146. The stock had a trading volume of 3,182,930 shares. Ocular Therapeutix has a 52 week low of $4.04 and a 52 week high of $11.91. The stock has a 50-day moving average price of $10.44 and a 200 day moving average price of $8.94. The stock’s market cap is $177.49 million.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.10. The firm had revenue of $0.48 million for the quarter, compared to analyst estimates of $0.51 million. Ocular Therapeutix had a negative return on equity of 110.89% and a negative net margin of 3,373.26%. During the same period in the prior year, the firm earned ($0.35) EPS. On average, equities analysts forecast that Ocular Therapeutix will post ($2.35) EPS for the current fiscal year.

OCUL has been the topic of several research reports. ValuEngine raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th. Zacks Investment Research raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Wednesday, March 22nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 price objective on shares of Ocular Therapeutix in a research report on Monday, May 15th. BTIG Research lowered Ocular Therapeutix from a “buy” rating to a “neutral” rating in a research report on Friday, May 5th. Finally, Morgan Stanley lowered Ocular Therapeutix from an “overweight” rating to an “equal weight” rating and set a $16.00 price objective on the stock. in a research report on Friday, June 23rd. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Ocular Therapeutix currently has a consensus rating of “Buy” and a consensus target price of $24.69.

WARNING: This news story was originally published by WKRB News and is owned by of WKRB News. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.wkrb13.com/markets/2285759/ocular-therapeutix-ocul-receives-news-impact-score-of-0-19.html.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285759/ocular-therapeutix-ocul-receives-news-impact-score-of-0-19.html

Receive News & Ratings for Ocular Therapeutix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.